Veterinary Parasiticides Market Report 2026

The veterinary parasiticides market size has grown strongly in recent years. It will grow from $15.53 billion in 2025 to $16.36 billion in 2026 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to high prevalence of parasitic infections in livestock, widespread use of conventional dewormers, expansion of commercial animal farming, increasing veterinary prescriptions for parasite control, availability of basic oral and injectable parasiticides.

The veterinary parasiticides market size is expected to see strong growth in the next few years. It will grow to $20.22 billion in 2030 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to rising pet ownership and companion animal care, increasing awareness of zoonotic parasite risks, growth in preventive veterinary healthcare, development of novel parasiticide formulations, expansion of veterinary clinic networks. Major trends in the forecast period include rising demand for broad-spectrum parasiticides, increasing adoption of combination and endectocide products, growth in preventive parasite control programs, higher focus on companion animal parasite management, expanding use of long-acting and sustained-release formulations.

The increasing adoption of pets worldwide is expected to propel the growth of the veterinary parasiticides market in the coming years. Pet adoption refers to the process of taking responsibility for and providing a permanent, caring home to a domesticated animal, often through animal shelters, rescue organizations, or previous owners. Pet owners who adopt animals tend to be more responsible and attentive to animal health, which leads to higher demand for parasiticides to protect pets from common parasites and maintain overall well-being. In addition, shelters and rescue organizations frequently provide initial parasite prevention treatments, further encouraging the continued use of parasiticides. For example, in April 2025, according to the Canadian Animal Health Institute, a Canada-based trade association, Canada was home to an estimated 7.2 million dogs and 8.2 million cats in 2024, making pets an essential part of more than half of Canadian households. Therefore, the growing adoption of pets is driving the growth of the veterinary parasiticides market.

Major companies operating in the veterinary parasiticides market are focusing on the development of innovative solutions such as long-acting injectable and broad-spectrum parasiticide formulations to address the increasing demand for extended protection against multiple parasite species, improved pet owner compliance, reduced treatment frequency, and comprehensive parasite control for companion animals and livestock. Long-acting injectable and broad-spectrum parasiticide formulations are designed to maintain effective levels of active ingredients over extended periods, offering protection against fleas, ticks, and internal parasites with a single administration. This approach provides greater convenience compared with traditional monthly oral or topical products, which require frequent dosing and are more prone to compliance challenges. For instance, in February 2025, Merck Animal Health, a U.S.-based animal health company, highlighted the injectable formulation of BRAVECTO (fluralaner), a parasiticide that provides up to 12 months of continuous flea and tick protection with a single dose. This formulation delivers sustained therapeutic concentrations of fluralaner throughout the year, reduces missed doses, simplifies parasite management, and supports animal welfare by minimizing the need for repeated treatments. Its extended-release mechanism and year-long duration represent a significant advancement over conventional parasiticides that typically require monthly or quarterly administration, thereby improving long-term parasite control and adherence to treatment regimens.

In July 2023, Freya Bidco Limited, a UK-based company, acquired Dechra Pharmaceuticals plc for approximately $5.47 billion (GBP 4.459 billion). Through this acquisition, EQT aims to support Dechra’s next phase of growth by accelerating global expansion and investing in the development of its innovative animal health product pipeline. Dechra Pharmaceuticals plc is a UK-based animal healthcare company specializing in the development, manufacturing, and supply of products for companion animals, equine, food-producing animals, and animal nutrition.

Major companies operating in the veterinary parasiticides market are Bayer AG, Zoetis Inc., Boehringer Ingelheim, Merck & Co. Inc., Ceva Animal Health, Dechra Pharmaceuticals plc, Phibro Animal Health Corporation, Bovian Health Care Pvt Ltd, Norbrook Laboratories Limited, Bimeda Holdings PLC, PetIQ Inc., ECO Animal Health Group plc, Bioniche Animal Health Canada Inc., Laboratorios Hipra SA, Elanco Animal Health Incorporated, Virbac, Huvepharma, Chanelle Pharma, Zydus Animal Health, KRKA d d.

North America was the largest region in the veterinary parasiticides market in 2025. Asia-Pacific was the second-largest region in the veterinary parasiticides market. The regions covered in the veterinary parasiticides market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the veterinary parasiticides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the veterinary parasiticides market by increasing costs of imported active pharmaceutical ingredients, chemical intermediates, and finished dosage formulations. These effects are most significant for oral tablets and injectable products used across farm and companion animals, particularly in Asia-Pacific, Europe, and North America where global sourcing is common. Higher input costs may pressure pricing and adoption in cost-sensitive farming regions. However, tariffs are encouraging domestic API manufacturing and localized formulation, supporting supply chain resilience and regional self-sufficiency.

The veterinary parasiticides market research report is one of a series of new reports that provides veterinary parasiticides market statistics, including veterinary parasiticides industry global market size, regional shares, competitors with a veterinary parasiticides market share, detailed veterinary parasiticides market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary parasiticides industry. This veterinary parasiticides market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Veterinary parasiticides are a class of animal medications used to combat parasites and improve the health of pets, livestock, and other animals. These medications work by inhibiting the activity of acetylcholinesterase, thus treating diseases caused by various parasites, such as helminths, amoeba, ectoparasites, parasitic fungi, protozoa, and others.

The primary types of veterinary parasiticides include endoparasiticides, ectoparasiticides, and endectocides. Endectocides are medications administered directly to hosts to target both endoparasites and ectoparasites, with a primary focus on blood-feeding arthropods. These parasiticides are available in various product forms, including oral liquids, tablets, injectables, sprays, and other formulations designed for farm animals and companion animals. They are commonly used by research and development facilities, farms, and veterinary clinics.

The veterinary parasiticides market consists of sales of macrocyclic lactones, benzimidazoles, imidazothiazoles, piperazines, and salicylanilides. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.